Dr Richard Jaine, Dr Giorgi Kvizhinadze, Prof Nick Wilson, Prof Tony Blakely
There is reasonably strong evidence screening for lung cancer with low-dose computed tomography (LDCT) scans is effective at reducing lung cancer mortality. However, new research suggests it is highly unlikely to be cost-effective in NZ. We have just published the first NZ study to examine the cost-effectiveness of lung cancer screening in the journal Lung Cancer, and we estimate that it would cost NZ$154,000 per quality-adjusted life-year (QALY) gained – even among heavy smokers . This means that gaining the equivalent of one year of life in perfect health from lung cancer screening comes with a price tag of about $150,000. This suggests that if we want to reduce the burden of lung cancer in NZ but still have to work within a finite health budget, we should consider more cost-effective means (e.g. enhanced tobacco control).